en · de · es · fr · pt
sr9009-notes.peptides3626.com › News › Background And Research Status — Background and Details

Background And Research Status — Background and Details

By Editorial Desk · published 2025-11-23 · last reviewed 2026-01-11 · News

Everything below concerns circadian rhythm. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-01-11. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Analytical Detection and Regulatory Status

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also referred to as Stenabolic in non-scientific contexts.
Chemical classSynthetic small moleculeNot a steroid or peptide hormone.
Receptor targetREV-ERBα and REV-ERBβNuclear receptor agonist in preclinical studies.
Development statusInvestigationalNo approved human therapeutic indication.
Regulatory attentionProhibited in sportListed by anti-doping authorities.

Analytical Detection and Stability

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Related pages on this site

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Background from the literature

== Modifications == The threonine residue is susceptible to numerous posttranslational modifications. The hydroxyl side-chain can undergo O-linked glycosylation. In addition, threonine residues undergo phosphorylation through the action of a threonine kinase. In its phosphorylated form, it can be referred to as phosphothreonine. Phosphothreonine has three potential coordination sites (carboxyl, amine and phosphate group) and determination of the mode of coordination between phosphorylated ligands and metal ions occurring in an organism is important to explain the function of the phosphothreonine in biological processes.

==== Investigation of Bruno Pacheco ==== On 16 November 2021, leaked chats showed that then presidential secretary Bruno Pacheco attempted to pressure the SUNAT to favor certain companies and individuals. On 19 November 2021, Bruno Pacheco resigned as presidential secretary due to his role in the Walter Ayala controversy, regarding attempts to irregularly promote military personnel. Pacheco maintained that he was resigning in order to stop the smear campaign against the President. His position was replaced by Carlos Jaico. On 23 November 2021, the Public Prosecutor's Office found $20,000 in cash inside Pacheco's office bathroom in the Governmental Palace. Pacheco claimed that this money came from his savings and the salary he received. On 24 November 2021, Alejandro Aguinaga, a Popular Force parliamentarian and president of the Congressional Oversight Commission called on Prime Minister Mirtha Vásquez to indicate what measures would be taken against Pacheco. In response, the Free Peru parliamentarian Guillermo Bermejo accused the Fujimorist Popular Force of double standards and brought up corruption charges against Alberto Fujimori and Vladimiro Montesinos. Meanwhile, the former prime minister Guido Bellido said "It makes me suspicious that someone goes to work with his 20 thousand dollars," and stated that it would be evaluated and taken into account in Free Peru's stance on the impeachment motion.

Ac-Aib-Pro-Aib-Ala-Aib-Ala-Gln-Aib-Val-Aib-Gly-Leu-Aib-Pro-Val-Aib-Aib-Glu-Gln-Phl where Ac = acetyl, Phl = phenylalaninol, and Aib = 2-Aminoisobutyric acid. In cell membranes, it forms voltage-dependent ion channels by aggregation of four to six molecules.

==== Early life stress ==== Epigenetic modifications including DNA methylation and histone acetylation regulate OPRK1 gene expression in response to environmental factors such as early life stress and psychological trauma. Decreased DNA methylation in intron 2 of OPRK1, functioning as a gene enhancer, has been observed in the anterior insula of individuals with histories of childhood abuse, which correlates with altered receptor expression and stress responsivity. Postmortem samples from suicide completers with a history of severe child abuse (CA) had higher rates of KOR downregulation relative to controls and suicide completers without CA history, an effect not accompanied by alterations in multiple other genes. Hypomethylation of OPRK1 intron 2 was associated with the CA group, as low levels of DNA methylation facilitate glucocorticoid binding and subsequent regulation of OPRK1 transcription. Additionally, a specific insertion deletion (INDEL) polymorphism, rs35566036, in the OPRK1 promoter region occurred more frequently in suicide completers with major depressive disorder relative to healthy controls.

=== Absorption === The oral bioavailability of testosterone is very low. The bioavailability of oral testosterone undecanoate is 3 to 7%. Topical testosterone gels have a bioavailability of about 8 to 14% when administered to recommended skin sites including the abdomen, arms, shoulders, and thighs. The bioavailability of testosterone by subcutaneous implant is virtually 100%. The bioavailability of drugs that are administered intramuscularly is generally almost 95%.

Sources: en.wikipedia.org

Reference notes

== History == 1993-2000 In 1994, Hetero began operating their first API manufacturing unit in Hyderabad, and by 1995 Hetero formalized its commitment to scientific research with the establishment of the Hetero Research Foundation (HRF). HRF is a dedicated research institution that serves as the engine of the company’s new medicine development and molecule work. By 1997, four years after its founding, Hetero emerged as one of the leading companies globally offering affordable antiretroviral APIs, having independently developed generic processes for more than 20 molecules. This placed Hetero at the forefront of the global effort to improve access to HIV/AIDS treatment in low income countries at a time when branded ARVs were incredibly expensive for the majority of patients. 2001-2005 Three years later, in 2001, Hetero received its first USFDA approval for an API facility in Hyderabad, marking the company’s formal entry into regulatory environments and laying the foundation for its subsequent US businesses. By 2005, Hetero broadened its capabilities beyond antiretrovirals and gained recognition as one of the first companies in India to develop and market the antiviral medication Oseltamivir, for the treatment of bird flu and swine flu. 2006-2009 In 2006, Hetero received USFDA approval for a finished dosage manufacturing facility in Hyderabad, an important development that enabled the company to supply generic formulations directly to the US market. This marked Hetero’s vertical integration from raw material production to patient ready medicines.

== Applications == LSF has been demonstrated in an alkaloid toxin (veratridine) and used to introduce an azobenzene group to control the toxin activity with light. The two reported LSF routes may allow introducing other functional groups like radioactive or fluorescent labels.

Independence also did not result in stable political regimes, save in a few countries. First, the new nations did not have well-defined identities; rather, the process of creating identities was only beginning. This process would be carried out through newspapers and the creation of national symbols, including new names for the countries ("Mexico", "Colombia", "Ecuador", "Bolivia", "Argentina"), that broke with the past. In addition, the borders were not firmly established, and the struggle between federalism and centralism, which began in independence, continued throughout the rest of the century. Two large states that emerged from the wars—Gran Colombia and the Federal Republic of Central America—collapsed after a decade or two, and Argentina would not consolidate politically until the 1860s. The wars destroyed the old civilian bureaucracy that had governed the region for centuries, as institutions such as the audiencias were eliminated and many Peninsular officials fled to Spain. The Catholic Church, which had been an important social and political institution during the colonial period, initially came out weakened by the end of the conflicts. As with government officials, many Peninsular bishops abandoned their dioceses and their posts were not filled for decades until new prelates could be created and relations between the new nations and the Vatican were regularized. Then as the Church recovered, its economic and political power was attacked by liberals.

Pakistan's fauna mirrors its diverse climate. The country boasts around 668 bird species, including crows, sparrows, mynas, hawks, falcons, and eagles. Palas, Kohistan, is home to the western tragopan, with many migratory birds visiting from Europe, Central Asia, and India. The southern plains harbor mongooses, small Indian civet, hares, the Asiatic jackal, the Indian pangolin, the jungle cat, and the sand cat. Indus is home to mugger crocodiles, while surrounding areas host wild boars, deer, and porcupines. Central Pakistan's sandy scrublands shelter Asiatic jackals, striped hyenas, wildcats, and leopards. The mountainous north hosts a variety of animals like the Marco Polo sheep, urial, markhor goat, ibex goat, Asian black bear, and Himalayan brown bear. The lack of vegetative cover, severe climate, and grazing impact on deserts have endangered wild animals. The chinkara is the only animal found in significant numbers in Cholistan, with a few nilgai along the Pakistan–India border and in some parts of Cholistan. Rare animals include the snow leopard and the blind Indus river dolphin, of which there are believed to be about 1,816 remaining, protected at the Indus Dolphin Reserve in Sindh. In total, 174 species of mammals, 177 species of reptiles, 22 species of amphibians, 198 species of freshwater fish, 668 species of birds, over 5,000 species of insects, and over 5,700 species of plants have been recorded in Pakistan.

Maurice Loyal Huggins (September 19, 1897, Berkeley, California – December 17, 1981) was a scientist who independently conceived the idea of hydrogen bonding and who was an early advocate for their role in stabilizing protein secondary structure. An important polymer theory, Flory–Huggins theory, is also named after him.

Sources: en.wikipedia.org

Notes from published material

==== Type II antithrombin deficiency ==== Type II antithrombin deficiency is characterized by normal antithrombin levels but reduced antithrombin activity in the blood of affected individuals. It was originally proposed that type II deficiency be further divided into three subgroups (IIa, IIb, and IIc) depending on which antithrombin functional activity is reduced or retained.

=== Children === In most countries, fluoroquinolones are only approved for use in children under narrowly defined circumstances, owing in part to the observation of high rates of musculoskeletal adverse events in fluoroquinolone-treated juvenile animals. The use of fluoroquinolones in those 18 years of age and under is only FDA approved for complicated UTI's (pyelonephritis and for postexposure prophylaxis) and treatment of inhalation anthrax. In the UK, the prescribing indications for fluoroquinolones for children are severely restricted. Only inhalational anthrax and pseudomonal infections in cystic fibrosis infections are licensed indications in the UK due to ongoing safety concerns. In a study comparing the safety and efficacy of levofloxacin to that of azithromycin or ceftriaxone in 712 children with community-acquired pneumonia, serious adverse events were experienced by 6% of those treated with levofloxacin and 4% of those treated with comparator antibiotics. Most of these were considered by the treating physician to be unrelated or doubtfully related to the study drug. Two deaths were observed in the levofloxacin group, neither of which was thought to be treatment-related. Spontaneous reports to the U.S. FDA Adverse Effects Reporting System at the time of the 20 September 2011 U.S. FDA Pediatric Drugs Advisory Committee included musculoskeletal events (39, including five cases of tendon rupture) and central nervous system events (19, including five cases of seizures) as the most common spontaneous reports between April 2005 and March 2008.

Having a mild form of alpha thalassemia has been demonstrated to protect against malaria and thus can be an advantage in malaria endemic areas, thus conferring a selective survival advantage on carriers (known as heterozygous advantage), and perpetuating the mutation. There are suggestions that mild beta thalassemia may provide similar protection but this has not been proven. α-thalassemia genes have a high prevalence in populations of sub-Saharan Africa, Mediterranean, Middle East, and southeast and east Asia. β-thalassemias are prevalent in the populations of the Mediterranean, Middle East, and Southeast Asia.

=== Fluorescence polarization === Fluorescence polarization (FP) is synonymous with fluorescence anisotropy. This method measures the change in the rotational speed of a fluorescent-labeled ligand once it is bound to the receptor. Polarized light is used in order to excite the ligand, and the amount of light emitted is measured. Depolarization of the emitted light depends on ligand being bound (e.g., to receptor). If ligand is unbound, it will have a large depolarization (ligand is free to spin rapidly, rotating the light). If the ligand is bound, the combined larger size results in slower rotation and therefore, reduced depolarization. An advantage of this method is that it requires only one labeling step. However, this method is less precise at low nanomolar concentrations.

== Ligands == D-serine was thought to exist only in bacteria until relatively recently; it was the second D amino acid discovered to naturally exist in humans, present as a signaling molecule in the brain, soon after the discovery of D-aspartate. Had D amino acids been discovered in humans sooner, the glycine site on the NMDA receptor might instead be named the D-serine site. Outside the central nervous system, D-serine plays a signaling role in peripheral tissues and organs such as cartilage, kidney, and corpus cavernosum.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Is SR9009 a steroid?

No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.

Has SR9009 been tested in humans?

Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Network